BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 35933338)

  • 21. Minimal residual disease and outcome characteristics in infant KMT2A-germline acute lymphoblastic leukaemia treated on the Interfant-06 protocol.
    Stutterheim J; de Lorenzo P; van der Sluis IM; Alten J; Ancliffe P; Attarbaschi A; Aversa L; Boer JM; Biondi A; Brethon B; Diaz P; Cazzaniga G; Escherich G; Ferster A; Kotecha RS; Lausen B; Leung AW; Locatelli F; Silverman L; Stary J; Szczepanski T; van der Velden VHJ; Vora A; Zuna J; Schrappe M; Valsecchi MG; Pieters R
    Eur J Cancer; 2022 Jan; 160():72-79. PubMed ID: 34785111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. KMT2A rearranged acute lymphoblastic leukaemia: Unravelling the genomic complexity and heterogeneity of this high-risk disease.
    Forgione MO; McClure BJ; Eadie LN; Yeung DT; White DL
    Cancer Lett; 2020 Jan; 469():410-418. PubMed ID: 31705930
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical features, early treatment responses, and outcomes of pediatric acute lymphoblastic leukemia in China with or without specific fusion transcripts: a single institutional study of 1,004 patients.
    Gao C; Zhao XX; Li WJ; Cui L; Zhao W; Liu SG; Yue ZX; Jiao Y; Wu MY; Li ZG
    Am J Hematol; 2012 Nov; 87(11):1022-7. PubMed ID: 22911440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Molecular detection of minimal residual disease is a strong predictive factor of relapse in childhood B-lineage acute lymphoblastic leukemia with medium risk features. A case control study of the International BFM study group.
    Biondi A; Valsecchi MG; Seriu T; D'Aniello E; Willemse MJ; Fasching K; Pannunzio A; Gadner H; Schrappe M; Kamps WA; Bartram CR; van Dongen JJ; Panzer-Grümayer ER
    Leukemia; 2000 Nov; 14(11):1939-43. PubMed ID: 11069029
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Minimal residual disease after intensive induction therapy in childhood acute lymphoblastic leukemia predicts outcome.
    Gruhn B; Hongeng S; Yi H; Hancock ML; Rubnitz JE; Neale GA; Kitchingman GR
    Leukemia; 1998 May; 12(5):675-81. PubMed ID: 9593264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. KMT2A (MLL) rearrangements observed in pediatric/young adult T-lymphoblastic leukemia/lymphoma: A 10-year review from a single cytogenetic laboratory.
    Peterson JF; Baughn LB; Pearce KE; Williamson CM; Benevides Demasi JC; Olson RM; Goble TA; Meyer RG; Greipp PT; Ketterling RP
    Genes Chromosomes Cancer; 2018 Nov; 57(11):541-546. PubMed ID: 30203571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hematopoietic stem cell transplantation for infants with high-risk KMT2A gene-rearranged acute lymphoblastic leukemia.
    Takachi T; Watanabe T; Miyamura T; Moriya Saito A; Deguchi T; Hori T; Yamada T; Ohmori S; Haba M; Aoki Y; Ishimaru S; Sasaki S; Ohshima J; Iguchi A; Takahashi Y; Hyakuna N; Manabe A; Horibe K; Ishii E; Koh K; Tomizawa D
    Blood Adv; 2021 Oct; 5(19):3891-3899. PubMed ID: 34500465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. MLL-Rearranged Acute Lymphoblastic Leukemia.
    El Chaer F; Keng M; Ballen KK
    Curr Hematol Malig Rep; 2020 Apr; 15(2):83-89. PubMed ID: 32350732
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Minimal residual disease-guided treatment deintensification for children with acute lymphoblastic leukemia: results from the Malaysia-Singapore acute lymphoblastic leukemia 2003 study.
    Yeoh AE; Ariffin H; Chai EL; Kwok CS; Chan YH; Ponnudurai K; Campana D; Tan PL; Chan MY; Kham SK; Chong LA; Tan AM; Lin HP; Quah TC
    J Clin Oncol; 2012 Jul; 30(19):2384-92. PubMed ID: 22614971
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse.
    Jacquy C; Delepaut B; Van Daele S; Vaerman JL; Zenebergh A; Brichard B; Vermylen C; Cornu G; Martiat P
    Br J Haematol; 1997 Jul; 98(1):140-6. PubMed ID: 9233577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies.
    Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A
    Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Reduced intensity of early intensification does not increase the risk of relapse in children with standard risk acute lymphoblastic leukemia - a multi-centric clinical study of GD-2008-ALL protocol.
    Li XY; Li JQ; Luo XQ; Wu XD; Sun X; Xu HG; Li CG; Liu RY; Sun XF; Chen HQ; Lin YD; Li CK; Fang JP
    BMC Cancer; 2021 Jan; 21(1):59. PubMed ID: 33435902
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Clinical significance of dynamic monitoring the minimal residual disease in childhood B-lineage acute lymphoblastic leukemia by multiparameter flow cytometry].
    Guo DD; Zhao WL; Zhang YL; Pang L; Che L; He HL; Chai YH; Ji ZH; Ji XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Dec; 20(6):1346-51. PubMed ID: 23257430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
    Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
    Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of minimal residual disease in infants with acute lymphoblastic leukemia treated within the Interfant-99 protocol.
    Van der Velden VH; Corral L; Valsecchi MG; Jansen MW; De Lorenzo P; Cazzaniga G; Panzer-Grümayer ER; Schrappe M; Schrauder A; Meyer C; Marschalek R; Nigro LL; Metzler M; Basso G; Mann G; Den Boer ML; Biondi A; Pieters R; Van Dongen JJ;
    Leukemia; 2009 Jun; 23(6):1073-9. PubMed ID: 19212338
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prognostic role of minimal residual disease in mature B-cell acute lymphoblastic leukemia of childhood.
    Mussolin L; Pillon M; Conter V; Piglione M; Lo Nigro L; Pierani P; Micalizzi C; Buffardi S; Basso G; Zanesco L; Rosolen A
    J Clin Oncol; 2007 Nov; 25(33):5254-61. PubMed ID: 18024872
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical importance of minimal residual disease testing in the therapy of childhood B-cell acute lymphoblastic leukemia].
    Ye QD; Gu LJ; Tang JY; Xue HL; Chen J; Pan C; Chen J; Dong L; Zhou M; Jiang LM
    Zhongguo Dang Dai Er Ke Za Zhi; 2008 Jun; 10(3):333-6. PubMed ID: 18554462
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia.
    Kamens JL; Nance S; Koss C; Xu B; Cotton A; Lam JW; Garfinkle EAR; Nallagatla P; Smith AMR; Mitchell S; Ma J; Currier D; Wright WC; Kavdia K; Pagala VR; Kim W; Wallace LM; Cho JH; Fan Y; Seth A; Twarog N; Choi JK; Obeng EA; Hatley ME; Metzger ML; Inaba H; Jeha S; Rubnitz JE; Peng J; Chen T; Shelat AA; Guy RK; Gruber TA
    Nat Commun; 2023 Feb; 14(1):809. PubMed ID: 36781850
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Genomics of next generation sequencing in pediatric B-acute lymphoblastic leukemia and its impact on minimal residual disease].
    Gao YY; Jia YJ; Qi BQ; Zhang XY; Chen YM; Zou Y; Guo Y; Yang WY; Zhang L; Wang SC; Zhang RR; Liu TF; Song Z; Zhu XF; Chen XJ
    Zhonghua Er Ke Za Zhi; 2023 Jun; 61(6):527-532. PubMed ID: 37312464
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical Implications of Minimal Residual Disease Detection in Infants With
    Stutterheim J; van der Sluis IM; de Lorenzo P; Alten J; Ancliffe P; Attarbaschi A; Brethon B; Biondi A; Campbell M; Cazzaniga G; Escherich G; Ferster A; Kotecha RS; Lausen B; Li CK; Lo Nigro L; Locatelli F; Marschalek R; Meyer C; Schrappe M; Stary J; Vora A; Zuna J; van der Velden VHJ; Szczepanski T; Valsecchi MG; Pieters R
    J Clin Oncol; 2021 Feb; 39(6):652-662. PubMed ID: 33405950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.